These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 16600647

  • 1. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients.
    Cazzola M, Mantero A, Santus P, Carlucci P, Mondoni M, Bosotti L, Centanni S.
    Pulm Pharmacol Ther; 2007; 20(3):258-64. PubMed ID: 16600647
    [Abstract] [Full Text] [Related]

  • 2. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A, Diotto P, Burgess C, Weatherall M, Holt S, Beasley R, Siebers R.
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [Abstract] [Full Text] [Related]

  • 3. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 4. Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: a randomized, placebo-controlled, double-blind, crossover study.
    Cazzola M, Paggiaro P, Palange P, Bjermer L, Ausin P, Carlsson LG, Ekelund J, Lotvall J.
    Clin Drug Investig; 2012 Mar 01; 32(3):147-55. PubMed ID: 22235841
    [Abstract] [Full Text] [Related]

  • 5. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
    Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S.
    Respir Med; 2003 May 01; 97(5):453-7. PubMed ID: 12735659
    [Abstract] [Full Text] [Related]

  • 6. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study.
    Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S.
    Pulm Pharmacol Ther; 2009 Feb 01; 22(1):44-9. PubMed ID: 19071226
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.
    Mahler DA, Waterman LA, Ward J, Gifford AH.
    J Aerosol Med Pulm Drug Deliv; 2014 Apr 01; 27(2):103-9. PubMed ID: 23745526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
    Aziz I, Hall IP, McFarlane LC, Lipworth BJ.
    J Allergy Clin Immunol; 1998 Mar 01; 101(3):337-41. PubMed ID: 9525449
    [Abstract] [Full Text] [Related]

  • 12. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects.
    Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE.
    Thorax; 2000 Aug 01; 55(8):650-6. PubMed ID: 10899240
    [Abstract] [Full Text] [Related]

  • 13. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial.
    Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K, Formoterol Study Group.
    Clin Ther; 2007 Oct 01; 29(10):2167-78. PubMed ID: 18042473
    [Abstract] [Full Text] [Related]

  • 14. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A, Szalai Z, Pullerits T, Radeczky E.
    Respirology; 2007 Sep 01; 12(5):732-9. PubMed ID: 17875063
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial.
    Condemi JJ.
    Clin Ther; 2001 Sep 01; 23(9):1529-41. PubMed ID: 11589265
    [Abstract] [Full Text] [Related]

  • 16. Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2-agonists arformoterol and salmeterol.
    Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ, Morganroth J.
    Medicine (Baltimore); 2008 Nov 01; 87(6):319-328. PubMed ID: 19011503
    [Abstract] [Full Text] [Related]

  • 17. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K, Janson C, Lisspers K, Jørgensen L, Stratelis G, Telg G, Ställberg B, Johansson G.
    J Intern Med; 2013 Jun 01; 273(6):584-94. PubMed ID: 23495860
    [Abstract] [Full Text] [Related]

  • 18. Profiles of measured and perceived bronchodilation. A placebo-controlled cross-over trial comparing formoterol and salmeterol in moderate persistent asthma.
    Schermer TR, Hoff WJ, Greefhorst AP, Creemers JP, Sips AP, Westbroek J, van Herwaarden CL.
    Pulm Pharmacol Ther; 2004 Jun 01; 17(4):205-12. PubMed ID: 15219265
    [Abstract] [Full Text] [Related]

  • 19. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action.
    Celik G, Kayacan O, Beder S, Durmaz G.
    Respiration; 1999 Jun 01; 66(5):434-9. PubMed ID: 10516540
    [Abstract] [Full Text] [Related]

  • 20. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.
    Wang J, Nie B, Xiong W, Xu Y.
    J Clin Pharm Ther; 2012 Apr 01; 37(2):204-11. PubMed ID: 21740451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.